{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:17:14Z","timestamp":1763741834237,"version":"3.45.0"},"reference-count":17,"publisher":"American Animal Hospital Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Acquired myasthenia gravis (MG) in dogs can present with focal or generalized weakness and is diagnosed by the presence of circulating antibodies to the acetylcholine receptor. Megaesophagus is the most common focal form of MG. Although exacerbation of MG has been associated with the use of fluoroquinolones in humans, it has not been previously described in dogs. The medical records of 46 dogs diagnosed with MG based on acetylcholine receptor antibody testing from 1997 to 2021 were retrospectively evaluated to identify any dogs who demonstrated exacerbation of MG after the administration of a fluoroquinolone. Exacerbation of MG, from focal to generalized, occurred in a median of 4.5 days after initiation of fluoroquinolone therapy in six dogs. In addition, one dog with generalized MG and megaesophagus developed pyridostigmine resistance subsequent to fluoroquinolone therapy. Marked improvement in generalized weakness was reported 36 hr after discontinuation of fluoroquinolone therapy alone in one dog and in combination with pyridostigmine in two dogs. Fluoroquinolone therapy was never stopped in three dogs who were euthanized because of severe weakness and one dog who died of respiratory arrest.<\/jats:p>","DOI":"10.5326\/jaaha-ms-7353","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:36:47Z","timestamp":1694705807000},"page":"249-254","source":"Crossref","is-referenced-by-count":0,"title":["Suspected Fluoroquinolone-Induced Exacerbation of Myasthenia Gravis in Dogs"],"prefix":"10.5326","volume":"59","author":[{"given":"Karen Marina Hernandez","family":"Guzman","sequence":"first","affiliation":[{"name":"From Ryan Veterinary Hospital, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania (K.M.H.G.); and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Harkin","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas (K.H.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3280","reference":[{"key":"i1547-3317-59-5-249-b1","series-title":"Neuromuscul Disord","first-page":"331","article-title":"Myasthenia gravis and congenital myasthenic syndromes in dogs and cats: a history and mini-review","volume":"26","author":"Shelton","year":"2016","unstructured":"Shelton\n              GD.\n            \n          \n          Myasthenia gravis and congenital myasthenic syndromes in dogs and cats: a history and mini-review. Neuromuscul Disord2016;26;331\u20134."},{"key":"i1547-3317-59-5-249-b2","series-title":"J Vet Intern Med","first-page":"50","article-title":"Clinical forms of acquired myasthenia gravis in dogs: 25 cases (1988-1995)","volume":"11","author":"Dewey","year":"1997","unstructured":"Dewey\n              CW,\n            \n            \n              Bailey\n              CS,\n            \n            \n              Shelton\n              DS,\n            \n            \n          \n          Clinical forms of acquired myasthenia gravis in dogs: 25 cases (1988-1995). J Vet Intern Med1997;11:50\u20137."},{"key":"i1547-3317-59-5-249-b3","series-title":"J Vet Intern Med","first-page":"1707","article-title":"Classification of myasthenia gravis and congenital myasthenic syndromes in dogs and cats","volume":"34","author":"Mignan","year":"2020","unstructured":"Mignan\n              T,\n            \n            \n              Targett\n              M,\n            \n            \n              Lowrie\n              M.\n            \n          \n          Classification of myasthenia gravis and congenital myasthenic syndromes in dogs and cats. J Vet Intern Med2020;34:1707\u201317."},{"key":"i1547-3317-59-5-249-b4","series-title":"J Vet Intern Med","article-title":"Clinical features and outcome of acquired myasthenia gravis in 94 dogs","volume":"1\u201312","author":"Forgash","year":"2021","unstructured":"Forgash\n              JT,\n            \n            \n              Chang\n              YM,\n            \n            \n              Mittelman\n              NS,\n            \n            \n          \n          Clinical features and outcome of acquired myasthenia gravis in 94 dogs. J Vet Intern Med2021;1\u201312."},{"issue":"3","key":"i1547-3317-59-5-249-b5","series-title":"J Vet Emerg Crit Care","first-page":"193","article-title":"Myasthenia gravis in dogs with an emphasis on treatment and critical care management","volume":"21","author":"Khorzad","year":"2011","unstructured":"Khorzad\n              R,\n            \n            \n              Whelan\n              M,\n            \n            \n              Sisson\n              A,\n            \n            \n          \n          Myasthenia gravis in dogs with an emphasis on treatment and critical care management. J Vet Emerg Crit Care2011;21(3):193\u2013208."},{"key":"i1547-3317-59-5-249-b6","series-title":"J Clin Med","first-page":"1537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"Sheikh","year":"2021","unstructured":"Sheikh\n              S,\n            \n            \n              Alvi\n              U,\n            \n            \n              Soliven\n              B,\n            \n            \n          \n          Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med2021;10:1537."},{"key":"i1547-3317-59-5-249-b7","series-title":"Acta Neurol Scand","first-page":"419","article-title":"Myasthenia gravis and ciprofloxacin","volume":"94","author":"Roquer","year":"1996","unstructured":"Roquer\n              J,\n            \n            \n              Cano\n              A,\n            \n            \n              Seoane\n              SL,\n            \n            \n          \n          Myasthenia gravis and ciprofloxacin. Acta Neurol Scand1996;94:419\u201320."},{"issue":"10","key":"i1547-3317-59-5-249-b8","series-title":"Drug Saf","first-page":"839","article-title":"Fluoroquinolone-associated myasthenia gravis exacerbation. Evaluation of postmarketing reports from the US FDA Adverse Event Reporting System and a literature review","volume":"34","author":"Jones","year":"2011","unstructured":"Jones\n              SC,\n            \n            \n              Sorbello\n              A,\n            \n            \n              Boucher\n              RM.\n            \n          \n          Fluoroquinolone-associated myasthenia gravis exacerbation. Evaluation of postmarketing reports from the US FDA Adverse Event Reporting System and a literature review. Drug Saf2011;34(10):839\u201347."},{"key":"i1547-3317-59-5-249-b9","series-title":"J Neurol Sci","first-page":"109","article-title":"Prulifloxacin as a trigger of myasthenia gravis","volume":"280","author":"Rossi","year":"2009","unstructured":"Rossi\n              M,\n            \n            \n              Lusini\n              G,\n            \n            \n              Biasella\n              A,\n            \n            \n          \n          Prulifloxacin as a trigger of myasthenia gravis. J Neurol Sci2009;280:109\u201310."},{"key":"i1547-3317-59-5-249-b10","series-title":"Muscle Nerve","first-page":"156","article-title":"Pharmacosafety of fluoroquinolone and macrolide antibiotics in the clinical care of patients with myasthenia gravis","volume":"64","author":"Nguyen","year":"2021","unstructured":"Nguyen\n              TPP,\n            \n            \n              Leonard\n              CE,\n            \n            \n              Bird\n              SJ,\n            \n            \n          \n          Pharmacosafety of fluoroquinolone and macrolide antibiotics in the clinical care of patients with myasthenia gravis. Muscle Nerve2021;64:156\u201362."},{"key":"i1547-3317-59-5-249-b11","series-title":"Front Mol Neurosci","first-page":"156","article-title":"Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments","volume":"13","author":"Krenn","year":"2020","unstructured":"Krenn\n              M,\n            \n            \n              Grisold\n              A,\n            \n            \n              Wohlfarth\n              P,\n            \n            \n          \n          Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments. Front Mol Neurosci2020;13:156."},{"key":"i1547-3317-59-5-249-b12","series-title":"Neurol Sci","first-page":"2255","article-title":"Exacerbation of myasthenia gravis after amoxicillin therapy: a case series","volume":"41","author":"Vacchiano","year":"2020","unstructured":"Vacchiano\n              V,\n            \n            \n              Solli\n              P,\n            \n            \n              Bartolomei\n              I,\n            \n            \n          \n          Exacerbation of myasthenia gravis after amoxicillin therapy: a case series. Neurol Sci2020;41:2255\u20137."},{"key":"i1547-3317-59-5-249-b13","unstructured":"FDA News Release. FDA updates warnings for fluoroquinolone antibiotics. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-updates-warnings-fluoroquinolone-antibiotics#:~:text=The%20FDA%20first%20added%20a,added%20to%20the%20Boxed%20Warning. Accessed March 3, 2022.","article-title":"FDA updates warnings for fluoroquinolone antibiotics"},{"key":"i1547-3317-59-5-249-b14","series-title":"J Emerg Med","first-page":"281","article-title":"Emergency department management of a myasthenia gravis patient with community-acquired pneumonia: does initial antibiotic choice lead to a cure or crisis?","volume":"50","author":"Van Berkel","year":"2016","unstructured":"Van Berkel\n              MA,\n            \n            \n              Twilla\n              JF,\n            \n            \n              England\n              BS.\n            \n          \n          Emergency department management of a myasthenia gravis patient with community-acquired pneumonia: does initial antibiotic choice lead to a cure or crisis?\n          \n            J Emerg Med\n          \n          2016;50:281\u20135."},{"key":"i1547-3317-59-5-249-b15","series-title":"J Am Vet Med Assoc","first-page":"1748","article-title":"Etiology and clinical outcome in dogs with aspiration pneumonia: 88 cases (2004-2006)","volume":"233","author":"Kogan","year":"2008","unstructured":"Kogan\n              DA,\n            \n            \n              Johnson\n              LR,\n            \n            \n              Sturges\n              BK,\n            \n            \n          \n          Etiology and clinical outcome in dogs with aspiration pneumonia: 88 cases (2004-2006). J Am Vet Med Assoc2008;233:1748\u201355."},{"key":"i1547-3317-59-5-249-b16","series-title":"Neurology","first-page":"804","article-title":"Fluoroquinolone antibiotics block neuromuscular transmission","volume":"50","author":"Sieb","year":"1998","unstructured":"Sieb\n              JP.\n            \n          \n          Fluoroquinolone antibiotics block neuromuscular transmission. Neurology1998:50:804\u20137."},{"key":"i1547-3317-59-5-249-b17","series-title":"Brain Res","first-page":"179","article-title":"Effects of the quinolone derivatives quinine, quinidine, and chloroquine on neuromuscular transmission","volume":"712","author":"Sieb","year":"1996","unstructured":"Sieb\n              JP,\n            \n            \n              Milone\n              M,\n            \n            \n              Engel\n              AG.\n            \n          \n          Effects of the quinolone derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Res1996;712:179\u201389."}],"container-title":["Journal of the American Animal Hospital Association"],"original-title":[],"link":[{"URL":"https:\/\/jaaha.kglmeridian.com\/view\/journals\/aaha\/59\/5\/article-p249.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jaaha\/article-pdf\/59\/5\/249\/3255992\/i1547-3317-59-5-249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jaaha.kglmeridian.com\/downloadpdf\/journals\/aaha\/59\/5\/article-p249.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jaaha.kglmeridian.com\/downloadpdf\/journals\/aaha\/59\/5\/article-p249.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:04:49Z","timestamp":1763741089000},"score":1,"resource":{"primary":{"URL":"https:\/\/jaaha.kglmeridian.com\/view\/journals\/aaha\/59\/5\/article-p249.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":17,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5326\/jaaha-ms-7353","relation":{},"ISSN":["1547-3317","0587-2871"],"issn-type":[{"type":"electronic","value":"1547-3317"},{"type":"print","value":"0587-2871"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}